ONGA
CORT icon

O'Neil Global Advisors’s Corcept Therapeutics CORT Stock Holding History

O'Neil Global Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.55M Buy
+98,334
New +$5.94M 1.91% 15
2025
Q1 		– Sell
-33,763
Closed -$1.7M – 28
2024
Q4 		$1.7M Buy
+33,763
New +$1.77M 0.5% 18

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

O'Neil Global Advisors's CORT Position: Q2 2026 in Review

O'Neil Global Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 98,334 shares worth $8.55M. The stake represents 1.91% of the portfolio and ranks #15 among its holdings. This is a return to the name: O'Neil Global Advisors previously reported a position in CORT as recently as Q4 2024.

O'Neil Global Advisors first reported a position in CORT in Q4 2024 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • O'Neil Global Advisors held 98,334 shares of Corcept Therapeutics worth $8.55M as of Q2 2026.
  • Corcept Therapeutics was a new O'Neil Global Advisors position in Q2 2026.
  • Corcept Therapeutics made up 1.91% of O'Neil Global Advisors's portfolio in Q2 2026, its #15 holding.
  • O'Neil Global Advisors first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on O'Neil Global Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.